Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809882 | 1.00 | EGFR (0.46) | EGFRMETAP2METAP1PIK3CGHSP90AA1 | |
| SCHEMBL30446266 | 0.84 | EGFR (0.37) | EGFR | |
| SCHEMBL3234117 | 0.81 | EGFR (0.43) | EGFRMETAP2METAP1PIK3CGPIK3CD | |
| SCHEMBL30826363 | 0.77 | EGFR (0.35) | EGFR | |
| SCHEMBL29364990 | 0.77 | EGFR (0.50) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL30502330 | 0.77 | EGFR (0.50) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL12414 | 0.77 | EGFR (0.50) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL5804048 | 0.77 | EGFR (0.35) | EGFRCDC25B | |
| SCHEMBL30876200 | 0.75 | EGFR (0.48) | EGFRMETAP2METAP1HSP90AA1PIK3CD | |
| SCHEMBL11385198 | 0.75 | CCR1 (0.50) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-11-18 | — | — | US | claimed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | claimed |
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-21 | — | — | US | claimed |
| US-6124306-A | Thioalkyl alpha substituted pyrimidine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-26 | — | — | US | claimed |
| EP-1034167-A1 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-13 | — | — | EP | claimed |
| WO-1999019304-A9 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | UPJOHN CO (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1999019304-A2 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0145337-B1 | ELECTROCHROMIC DEVICES | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1990-08-08 | — | — | EP | claimed |
| EP-0096723-B1 | BATTERIES FABRICATED WITH ELECTROACTIVE POLYMERS | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1988-08-10 | — | — | EP | claimed |
| US-4613211-A | REVERSE COLOR CHANGING POLYMER FILM AS DISPLAY ELECTRODE | CHEVRON RESEARCH COMPANY (US) | 1986-09-23 | — | — | US | claimed |
| US-4579679-A | Electroactive polymers | CHEVRON RESEARCH COMPANY (US) | 1986-04-01 | — | — | US | claimed |
| EP-0145337-A2 | Electrochromic devices | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1985-06-19 | — | — | EP | claimed |
| JP-51136695-A | — | — | None | — | — | JP | disclosed |
| EP-4741383-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-4519938-A | TRACTABLE, DOPED HETEROCYCLIC RINGS | CHEVRON RESEARCH COMPANY (US) | 1985-05-28 | — | — | US | disclosed |
| US-4038394-A | Substituted pyrimido-[4,5-d]-pyrimidine compounds useful for repelling insects, rodents or animals from substrates | CELANESE CORPORATION (US) | 1977-07-26 | — | — | US | disclosed |
| JP-S51136695-A | PROCESS FOR PREPARING NEW PYRIMIDO(4,5-D)PYRIMIDINE DERIVATIVES | HISAMITSU PHARMACEUT CO INC | 1976-11-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | EGFR 3119/4885METAP2 310/4885METAP1 667/4885 |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | EGFR 3119/4885METAP2 310/4885METAP1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.